[속보] 2024 ASCO 2건 초록 타이틀 최초 공개

****지아이이노베이션(358570)

# GI-102


A first-in-human, phase 1/2a study of GI-102 (CD80-IL2v3) in patients with advanced or metastatic solid tumors: Initial results from dose escalation.


(https://meetings.asco.org/abstracts-presentations/233987 )

# GI-101과 병용(지아이셀)


The promising feeder-free allogenic NK cell therapy: Clinical outcomes of GIC-102 monotherapy (GIC-102101) and synergistic potential with GI-101 (CD80-IgG4 Fc-IL2v) in advanced solid tumors and hematologic malignancies.


(https://meetings.asco.org/abstracts-presentations/235393 )